Received Nov 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | OT |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | — | OT |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 3 | — | OT |
patient was administered a 3rd dose of VAQTA following an early administration of the 2nd dose; No symptoms reported; 2nd dose on 7/3/2024. First dose was administered on 1/18/2024; This spontaneous report was received from a health care professional (office manager) concerning a 1 -year-old patient of unknown gender. The patient's medical history, past medications, concurrent conditions, concomitant medications and drug reactions/allergies were not reported. On 18-Jan-2024, the patient was vaccinated with the first dose of Hepatitis A Vaccine, Inactivated suspension for injection (VAQTA), 0.50 mL (batch/lot number, expiration date, anatomical location and route of administration were not reported). On 03-Jul-2024, the patient received early administration of the 2nd dose of Hepatitis A Vaccine, Inactivated suspension for injection (VAQTA), 0.50 mL (batch/lot number, expiration date, anatomical location and route of administration were not reported) (inappropriate schedule of product administration). Then, on unspecified date, patient was administered a 3rd dose of Hepatitis A Vaccine, Inactivated suspension for injection (VAQTA), 0.50 mL (batch/lot number, expiration date, anatomical location and route of administration were not reported) (extra dose administered). All three vaccine doses were administered as prophylaxis. There were no symptoms reported (no adverse event.) Batch/lot# is being requested and will be submitted if received.